Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

Inclusion Criteria: * Male or female ≥ 12 to ≤ 80 years of age at the time of signing the informed consent * Diagnosis of HoFH based on low-density lipoprotein cholesterol (LDL-C), familial history and xanthoma * On a low-fat diet and receiving background lipid-lowering therapy stable for 4 weeks prior to screening and during the time frame of the trial * Fasting LDL-C at screening \> 130 mg/dL (3.4 mmol/L) * Fasting triglycerides at screening ≤ 400 mg/dL (4.5 mmol/L) Exclusion Criteria: * Use of mipomersen or lomitapide within 6 months of screening. * Known active infection or major hematologic, renal, metabolic, gastrointestinal, hepatic, or endocrine dysfunction * Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies) * Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed * Female subjects of childbearing potential unwilling to use an acceptable method of effective contraception * Subject has known sensitivity to any of the products to be administered during dosing * History or evidence of any other clinically significant disorder, condition or disease * Subject has previously received evolocumab or any other proprotein convertase subtilisin/kexin type 9 (PKSK-9)-inhibiting therapy